Usefulness of mid-regional pro-adrenomedullin for stratifying risk in emergency department patients with solid tumors attended for febrile neutropenia secondary to chemotherapy

What Was Tested

The paper reports a study of Adrenomedullin, published as an observational study.

To analyze the usefulness of mean mid-regional pro-adrenomedullin (MR-proADM) level to stratify risk in emergency department patients with solid tumors attended for febrile neutropenia after chemotherapy.

To compare risk prediction with MR-proADM to that of conventional biomarkers and scores on the Multinational Association for Supportive Care in Cancer (MASCC) score.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Prospective observational cohort study enrolling patients with solid tumors who developed febrile neutropenia after chemotherapy.

The main outcome was the development of serious complications that were not present when febrile neutropenia was detected.

How the Study Was Run

The researchers collected demographic and tumor variables, the suspected focus of infection, and other variables necessary for calculating the MASCC score.

The following biomarkers were measured: C-reactive protein (CRP), procalcitonin, and MR-proADM.

What Was Measured

Topics PubMed links to this paper include Adrenomedullin, Neoplasms, Emergency Service, Hospital, Protein Precursors, Risk Assessment, Biomarkers and Procalcitonin.

The authors tagged it with the keywords C-reactive protein, Cancer, Escala MASCC, Estratificación del riesgo, MR-proADM and Mid-regional pro-adrenomedullin (MR-proADM).

What This Means in Plain Language

This is an observational study of Adrenomedullin.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias), a journal based in Spain.

More context: the Adrenomedullin compound page, all human trials.